Theriva Biologics, Inc. (TOVX): Theriva™ Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results
Theriva Biologics, Inc. (TOVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Theriva™ Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results – VIRAGE2 enrollment expected to complete in Q4 2026; initial data expected by Q3 2027 – – Company completes sale of SYN-004 (ribaxamase) and related portfolio of antibiotic-de
How this was made
The 30-second read
Why it matters
The combination of cash from the asset sale and positive trial data provides a dual catalyst for the stock.
Market read
New financial and clinical information may prompt short‑term buying pressure and longer‑term valuation reassessment.
What to watch
Potential regulatory milestones and royalty streams could be larger than implied, affecting long‑term upside.
Theriva reports Q3 2026 net loss of $1,471 thousand versus $4,361 thousand a year earlier, with no license revenue in the quarter and cash of $8.5 million
The quarter had no revenue and a net loss of $1,471 thousand, with cash of $8,473 thousand at September 30, 2026 and a company-stated runway into Q1 2027. The lower expense base improved the loss year over year, but the filing contains no product or licensing revenue for the quarter and the company says it is evaluating strategic alternatives.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| License revenue, three months ended Sept 30, 2026GAAP | shown as a dash (no amount reported) | – | – |
| License revenue, nine months ended Sept 30, 2026GAAP | $300K | – | – |
| General and administrative expenses, three months ended Sept 30, 2026GAAP | $923K | – | decrease of 51% |
| Research and development expenses, three months ended Sept 30, 2026GAAP | $612K | – | decrease of 76% |
| Total operating costs and expenses, three months ended Sept 30, 2026GAAP | $1.53M | – | – |
| Loss from operations, three months ended Sept 30, 2026GAAP | −$1.53M | – | – |
| Foreign currency exchange gain, three months ended Sept 30, 2026GAAP | shown as a dash (no amount reported) | – | – |
| Interest income, three months ended Sept 30, 2026GAAP | $64K | – | – |
| Total other income, three months ended Sept 30, 2026GAAP | $64K | – | – |
| Net loss before income taxes, three months ended Sept 30, 2026GAAP | −$1.47M | – | – |
| Income tax benefit, three months ended Sept 30, 2026GAAP | shown as a dash (no amount reported) | – | – |
| Net loss attributable to common stockholders, three months ended Sept 30, 2026GAAP | −$1.47M | – | – |
| Net loss per share, basic and diluted, three months ended Sept 30, 2026GAAP | $(0.03) | – | – |
| Total comprehensive loss, three months ended Sept 30, 2026GAAP | −$1.58M | – | – |
| General and administrative expenses, nine months ended Sept 30, 2026GAAP | $5.03M | – | – |
| Research and development expenses, nine months ended Sept 30, 2026GAAP | $2.23M | – | – |
| Total operating costs and expenses, nine months ended Sept 30, 2026GAAP | $7.26M | – | – |
| Loss from operations, nine months ended Sept 30, 2026GAAP | −$6.96M | – | – |
| Foreign currency exchange gain, nine months ended Sept 30, 2026GAAP | $1K | – | – |
| Interest income, nine months ended Sept 30, 2026GAAP | $226K | – | – |
| Total other income, nine months ended Sept 30, 2026GAAP | $227K | – | – |
| Net loss before income taxes, nine months ended Sept 30, 2026GAAP | −$6.73M | – | – |
| Net loss attributable to common stockholders, nine months ended Sept 30, 2026GAAP | −$6.73M | – | – |
| Net loss per share, basic and diluted, nine months ended Sept 30, 2026GAAP | $(0.15) | – | – |
| Total comprehensive loss, nine months ended Sept 30, 2026GAAP | −$7.35M | – | – |
| Cash and cash equivalents, as of Sept 30, 2026GAAP | $8.47M | – | – |
| Total assets, as of Sept 30, 2026GAAP | $31.56M | – | – |
| Total stockholders' equity, as of Sept 30, 2026GAAP | $10.75M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
What drove it
- Company explanation for the G&A decrease: a $841,000 decrease in the fair value of contingent consideration recognized in the three months ended September 30, 2026, compared with a $633,000 increase recognized in the same period in 2025, partially offset by a current year increase in legal fees.
- Stock-based compensation within G&A was $119,000 for the three months ended September 30, 2026, compared with $118,000 for the three months ended September 30, 2025.
- Company explanation for the R&D decrease: lower direct expenses from completion of the VCN-01 Phase 2b PDAC trial, lower direct expenses for VCN-01 manufacturing, lower direct clinical trial expenses for the paused Phase 1b/2a SYN-004 trial in allogeneic HCT recipients, and lower expenses for SYN-020, partially offset by costs of the VIRAGE2 Phase 2a study.
- Other income for the three months ended September 30, 2026 consisted of $64,000 of interest income. Other income for the three months ended September 30, 2025 consisted primarily of $65,000 of interest income and a $14,000 exchange gain.
- SYN-004 asset sale to Biossil Labs Inc. completed in October 2026: $350,000 upfront, up to $3 million in regulatory milestones and up to $88 million in sales milestones, plus single-digit royalties on net product sales capped at $250 million. The filing states the release headline figure as up to $91 million in aggregate milestones.
- Concurrent amendment with PREV ABR LLC: Theriva paid PREV ABR $140,000 upon receipt of the $350,000 upfront, and will pay 50% of future regulatory and sales milestones, 33⅓% of royalties received, and 50% of other consideration, up to an aggregate total of $13 million.
Concerns
- No revenue or license income was reported for the three months ended September 30, 2026.
- Cash and cash equivalents of $8.5 million, with a company-stated runway into Q1 2027, are short of the timing of the VIRAGE2 initial data (expected by Q3 2027).
- The company states it continues to evaluate strategic alternatives, which may include a business combination, merger or reverse merger, and its forward-looking statements cite the need to raise capital.
- Planned clinical trials are subject to sufficient financing, according to the forward-looking statements.
- Total stockholders' equity fell from $15,383 thousand at December 31, 2025 to $10,753 thousand at September 30, 2026.
What to watch
- VIRAGE2 Phase 2a enrollment completion, expected in Q4 2026 (two thirds of the 6 evaluable patients, 4, have been dosed).
- Initial pharmacodynamic and safety/tolerability data from VIRAGE2, anticipated by Q3 2027.
- Further FDA interactions on the proposed Phase 2/3 retinoblastoma trial, anticipated in Q1 2027 (a Type C meeting was completed August 31, 2026).
- Outcome of the strategic alternatives review.
- Cash runway into Q1 2027 and any financing or partnership announcements.
- Biossil milestone and royalty payments, which are contingent on future events.
- Eligibility for a Priority Review Voucher if a retinoblastoma BLA is approved by September 30, 2029.
Balance sheet and cash flow
- Cash and cash equivalents were $8.5 million as of September 30, 2026, a decrease of $4.6 million from December 31, 2025, when the balance sheet showed $13,056 thousand. The table shows $8,473 thousand at September 30, 2026.
- Total assets were $31,560 thousand at September 30, 2026, against $38,239 thousand at December 31, 2025.
- Total liabilities were $20,807 thousand at September 30, 2026, against $22,856 thousand at December 31, 2025.
- Total stockholders' equity was $10,753 thousand at September 30, 2026, against $15,383 thousand at December 31, 2025.
- Non-current contingent consideration was $8,978 thousand at September 30, 2026, against $10,004 thousand at December 31, 2025.
- Accrued expenses were $6,459 thousand at September 30, 2026, against $6,276 thousand at December 31, 2025.
- The company states a cash runway into Q1 2027.
- The filing states that the primary use of cash in the year ended December 31, 2025 and the nine months ended September 30, 2026 was for working capital requirements and operating activities, which resulted in a net loss of $23.7 million for 2025 and $6.7 million for the nine months ended September 30, 2026.
Analysis
Theriva reported a third quarter 2026 net loss of $1,471 thousand, against $4,361 thousand in the third quarter of 2025. The quarter recorded no license revenue, and the nine-month period included $300 thousand of license revenue with no comparable amount in the prior-year period. Operating costs fell sharply: G&A was $923 thousand against $1,889 thousand, a decrease the filing describes as 51%, and R&D was $612 thousand against $2,551 thousand, a decrease the filing describes as 76%. The company attributes the G&A decline mainly to a change in the fair value of contingent consideration, which moved from a $633,000 increase in the prior-year quarter to an $841,000 decrease in the current quarter, partly offset by higher legal fees. The R&D decline is attributed to the completion of the VCN-01 Phase 2b trial, lower manufacturing and SYN-004 trial costs, and lower SYN-020 expenses, partly offset by VIRAGE2.
On the nine-month view, total operating costs were $7,259 thousand against $21,988 thousand, and the net loss was $(6,732) thousand against $(21,743) thousand. Basic and diluted loss per share was $(0.15) for the nine months against $(3.38) a year earlier. The filing does not give a per-share figure for the quarter beyond $(0.03) against $(0.45), and the weighted share count rose sharply, so the per-share comparison is not like-for-like with the reduced loss in absolute terms.
The balance sheet is the main pressure point. Cash and cash equivalents were $8,473 thousand at September 30, 2026, down from $13,056 thousand at December 31, 2025, and total stockholders' equity was $10,753 thousand against $15,383 thousand. The company states a cash runway into Q1 2027. Its forward-looking statements also state that planned trials remain subject to sufficient financing and that the company may raise capital or enter a strategic transaction.
The quarter's other notable event is the sale of the SYN-004 and related antibiotic-degrading enzyme portfolio to Biossil Labs Inc., completed in October 2026. The company received a $350,000 upfront payment, and it paid PREV ABR $140,000 from that amount. Future milestone, royalty and other proceeds are shared with PREV ABR, up to an aggregate $13 million. The milestones and royalties are contingent on future events and are not yet reflected in the reported figures.
Management's stated focus is VCN-01. VIRAGE2 enrollment is expected to complete in Q4 2026, with initial data anticipated by Q3 2027. The retinoblastoma Phase 2/3 design remains under discussion with the FDA. The Nature Medicine publication of the VIRAGE Phase 2b analyses is cited by management as support for the program.
Management, verbatim
We are pleased with the clinical progress achieved this quarter.
Steven A. Shallcross, Chief Executive Officer, Theriva Biologics
In parallel, we continue to evaluate strategic alternatives intended to maximize value for our stockholders.
Steven A. Shallcross, Chief Executive Officer, Theriva Biologics
Not in the filing
stated, not guessed- No prior-period outlook was provided, so no comparison against prior guidance is possible.
- The filing reports no numeric financial guidance for future periods.
- No consolidated cash flow statement is included, so operating cash flow, investing cash flow and financing cash flow are not reported.
- No segment or geographic revenue breakdown is provided.
- Q3 2026 total revenue has no amount beyond the dash shown for license revenue.
- Year-over-year and quarter-over-quarter percentage changes are not printed for total operating costs, loss from operations, net loss, net loss per share or comprehensive loss, so those fields are null.
- Prior-quarter (June 30, 2026) figures are not printed, so all prior_quarter and qoq_change fields are null.
- The December 31, 2025 balance sheet figures are not a prior-year same-period comparison, so the balance sheet key metrics have null prior_year fields; those comparisons appear in balance_sheet_cash_flow.
- No capital return activity (share repurchases or dividends) is reported.
- The filing does not state the number of new shares issued or any financing proceeds in the period, although share counts rose from 35,717,159 issued at December 31, 2025 to 45,921,478 at September 30, 2026.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Theriva Biologics filed an 8‑K reporting Q3 2026 results, an asset sale, and clinical trial updates.
Ticker impact
Theriva reported a $350k upfront payment for the SYN-004 asset sale and disclosed upcoming enrollment completion and data readout from its VIRAGE2 trial.
likely modest upside as investors price in cash proceeds and trial progress
New cash infusion and clinical data are primary catalysts; no immediate large‑scale financing disclosed.
Market effects
Biotech sector may see increased interest in oncolytic adenovirus programs.
US biotech investors could adjust exposure to early‑stage oncology assets.
Limited to niche oncology and microbiome asset markets.
Counterpoint
The modest cash proceeds may be insufficient to sustain operations, risking dilution if further financing is needed.
Key entities
- companyTheriva Biologics, Inc.
Clinical‑stage biotech developing VCN‑01.
- companyBiossil Labs Inc.
Acquirer of Theriva's SYN‑004 enzyme portfolio.
